Immune checkpoint inhibitors (ICIs) improve the prognosis of GC patients, among which PD-L1/PD-1 inhibitors have good anti-tumor immunological effectiveness (Chen et al., 2021; Chen et al., 2022). Here, CD274 is linked to neoplasm.